Article

Ocular toxicity of ethambutol.

Department of Ophthalmology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong.
Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine 03/2006; 12(1):56-60.
Source: PubMed

ABSTRACT To review the literature on ocular toxicity of ethambutol--its background, clinical presentation, toxicity characteristics, management, monitoring, and preventive measures.
Literature search of Medline from 1962 to May 2005.
All related literature in English using the search formula: (ethambutol OR myambutol) AND (eye* OR ophthal* OR ocular) AND (adverse OR toxic).
All information was collected and analysed by authors.
Ethambutol hydrochloride is a commonly used first-line anti-tuberculous agent. Although rare, ocular toxicity in the form of optic neuritis (most commonly retrobulbar neuritis) has been well documented since its first use in the 1960s. Classically described as dose- and duration-related and reversible on therapy discontinuation, reversibility of optic neuritis remains controversial. International guidelines on prevention and early detection of ethambutol-induced ocular toxicity have been published. Nonetheless, opinion of the clinical effectiveness of regular vision tests to enable early detection of toxicity is divided.
The course of ethambutol-induced ocular toxicity is unpredictable. Measures to ensure a high level of awareness in medical staff and patients of this potential adverse effect appear to be the best current preventive method. Classified by the World Health Organization as a place with an intermediate tuberculosis burden and good health infrastructure, Hong Kong is in a good position to examine the unanswered questions about ethambutol-induced ocular toxicity.

1 Bookmark
 · 
248 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ethambutol (EMB) is one of the first-line antimycobacterial drugs used to treat tuberculosis and is also used to treat atypical mycobacterium infections. It is almost always used in combination with other antimycobacterial drugs. Ever since the drug’s introduction in the 1960s, there have been descriptions of optic neuropathy associated with EMB. Despite a clear association of EMB-induced optic neuropathy, many questions remain unanswered, namely, which tests are more accurate to monitor toxicity, how often should they be performed and once the optic neuropathy is present, how much of it is reversible?
    Expert Review of Ophthalmology 03/2014; 9(2).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Effective monitoring of antitubercular drugs including ethambutol (EMB) is important for control of multiple drug resistance. Development of fast, easy and inexpensive methods for detection of low concentrations of EMB, especially near its minimum inhibitory concentration, is important. Results: UPLC method for estimating EMB in rat plasma is developed and validated. The method uses small injection volume (1µl) and elutes EMB at 3.18min with 0.070µg/ml and 0.250µg/ml as limits of detection and quantification, respectively. The intra and inter-day accuracy was 106.01-108.82% and 107.80-109.00%, respectively with precision of <5% in both the cases. Mean extraction recovery of EMB from rat plasma was >97% at three concentration levels, establishing consistency and reproducibility (n=6) of the method. EMB was found to be stable in plasma under different storage and processing conditions. Conclusion: Study reports a highly sensitive and specific isocratic UPLC method for rapid quantization of EMB for use in pharmacokinetics and therapeutic drug monitoring
    RSC Advances 08/2014; · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The present study was designed to explore the antioxidative status and circulating biochemical markers having a potential role in the pathogenesis of ethambutol (EMB) induced toxic optic neuropathy (TON) among diabetic and non-diabetic patients. Material and method Fifty patients under complete therapy of EMB for tuberculosis were included in the present study. Inclusion criteria for patients were to receive EMB everyday during treatment, a dose of 25 mg/kg for initial two months and 15 mg/kg during rest of therapy period. We conducted color vision and visual acuity test for all patients. Results Fifteen out of fifty EMB induced TON patients, were found to be diabetic. Color vision and visual acuity test results were evaluated for diabetic and non-diabetic as well as twenty age matched controls. The results demonstrated a significant pattern of circulating biochemical markers between the studied groups. Data regarding hematological (RBC, p value =0.02; Hemoglobin, p value =0.02), hepatic (total bilirubin, p value =0.01), renal (urea, p value =0.03; creatinine, p value =0.007), lipid (total chotesterol, p value =0.01; total triglycerides, p value =0.03) and antioxidative (superoxide dismutase, p value =0.005; glutathion, p value =0.02; catalase, p value =0.02) profile showed a highly significant difference among the studied groups specially patients with diabetes. Malondialdehyde (MDA) level had gone significantly up in diabetic TON patients (p value = 0.02), in comparison to other antioxidants and vitamins (Vit). Vit- A, E, B1, B12 and Zinc seems to be playing a major role in the pathogenesis of TON, specially Vit-E and B1 surpassed all the antioxidants as having highly significant inverse relationships with MDA (MDA Vs Vit-E, r = -676∗∗ and MDA Vs Vit-B1, r = -724∗∗ respectively). Conclusion We conclude that during the ethambutol therapy the decreased levels of Vit-E and Vit-B1 possibly play a role in the development of TON and may be used as therapeutic agents to lessen the deleterious effects of ethambutol.
    Saudi Journal of Biological Sciences 01/2014; · 0.74 Impact Factor

Full-text

Download
5 Downloads
Available from